Q-omics provides the consensus-scored ZNF680P1 profile across patient tissues and cancer cell-line models. ZNF680P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF680P1 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, ZNF680P1 RNA expression shows 12,754 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ZNF680P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF680P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF680P1 survival associations across molecular data types. ZNF680P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF680P1 RNA expression–survival associations across cancer types. High ZNF680P1 expression shows unfavorable associations in KIRC, UCEC, CHOL and PCPG, but favorable associations in UCS and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF680P1 RNA expression.
This table summarizes ZNF680P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF680P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF680P1 shows lower tumor expression in THCA and LUSC and higher tumor expression in LIHC, KIRP and LUAD. The LIHC box plot shows higher ZNF680P1 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .004).
This table shows molecular features associated with ZNF680P1 in patient tissues and cancer cell lines. In patient samples, ZNF680P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
